Owkin Rolls Out Its Landmark AI Diagnostic Within Medipath, the Largest Network of Pathologists in France

June 14, 2023 3:00 AM

World's first AI diagnostic for MSI prescreening from routine H&E slides for colorectal cancer aims to help pathologists and oncologists facilitate better access to approved immunotherapy treatments for their patients.PARIS, FRANCE / ACCESSWIRE / June 14, 2023 / Owkin has successfully validated its MSIntuit™ CRC AI solution for colorectal cancer (CRC) screening, a major milestone in the use of AI to further improve precision...

Read more

Dermata Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET

June 13, 2023 4:15 PM

SAN DIEGO, CA / ACCESSWIRE / June 13, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA, DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, announced today that Dermata's CEO, Gerald Proehl, has been invited to present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, on Tuesday, June 20th to Thursday, June...

Read more

BioInvent Announces Abstract Presentation of BI-1206 at the 17th International Conference of Malignant Lymphoma 2023

June 13, 2023 2:20 AM

LUND, SWEDEN / ACCESSWIRE / June 13, 2023 / BioInvent International (STO:BINV) Abstract for the ongoing clinical trial with BI-1206 in combination with rituximab has been accepted to the ICML and showcases the study design and status, and summarizes the early clinical results generated so far in the dose escalation phase.Lund, Sweden - June 13, 2023 - BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on...

Read more

Lexaria Appoints New Chief Financial Officer

June 12, 2023 9:20 AM

KELOWNA, BC / ACCESSWIRE / June 12, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the appointment of a new Chief Financial Officer.Effective immediately, Mike Shankman has been appointed as outsourced CFO. Mike is an experienced accounting and finance professional who has held senior positions with companies in the biotechnology, medical devices,...

Read more

Neobiosis Announces FDA Approval of IND for Use of ViXomeTM in COVID-19 'Post Covid Syndrome'

June 12, 2023 9:00 AM

GAINESVILLE, FL / ACCESSWIRE / June 12, 2023 / Neobiosis, is a leading research and manufacturing biotechnology company focused on pioneering the development of novel therapeutics from perinatal tissues as a new class of medicines. Today, Neobiosis announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for ViXome™, its drug for the treatment of 'Post COVID Syndrome (AKA "Long...

Read more

Biovica Signs Provider Contract with Provider Network Contigo Health ConfigureNet(TM)

June 10, 2023 6:55 AM

UPPSALA, SWEDEN / ACCESSWIRE / June 10, 2023 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica today announces that it has signed a provider contract with Contigo Health ConfigureNet™ provider network. This commercial agreement will make Biovica's blood test, DiviTum® TKa, available to clients and their health plan members served by clients of Contigo Health."This important agreement represents another significant...

Read more

MyFloraDNA Researchers Develop Advanced Hop Latent Viroid (HLVd) Testing Strategies for Cannabis Cultivation: Sample Collection and Beyond

June 9, 2023 5:00 PM

SACRAMENTO, CA / ACCESSWIRE / June 9, 2023 / MyFloraDNA, a frontrunner in plant research, is excited to announce a milestone in the fight against Hop Latent Viroid (HLVd) in cannabis cultivation. This study, conducted in partnership with a major cannabis cultivation facility, provides advanced testing strategies and unravels crucial insights into HLVd detection.Addressing the pressing need for reliable and robust cannabis research, this study...

Read more

Abivax Stock Included in MSCI Indexes

June 8, 2023 12:10 PM

As of June 1st, the Abivax stock is represented in the MSCI IndexesThe MSCI Indexes reflect the evolution of the world's equity markets to support investors building effective portfolios based on risk and return assessmentsPARIS, FRANCE / ACCESSWIRE / June 8, 2023 / Abivax (Euronext Paris: FR0012333284 - ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with...

Read more

Abivax Appoints Ida Hatoum as Chief People Officer

June 8, 2023 10:40 AM

As Chief People Officer of Abivax, Ida Hatoum will be leading the organizational strategy to build and strengthen the Abivax team in the United States and Europe across all functionsIda has a proven track record in talent acquisition and development in the biopharmaceutical industryPARIS, FRANCE / ACCESSWIRE / June 8, 2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX), a Phase 3 clinical-stage biotechnology company focused on developing...

Read more

Nascent Biotech Phase I Clinical Data Presented at the American Society of Clinical Oncology Annual Meeting

June 7, 2023 8:00 AM

NORTH PALM BEACH, FL / ACCESSWIRE / June 7, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company whose business is focused in therapeutic monoclonal antibody space presented their Phase I Clinical Data at the American Society of Clinical Oncology (ASCO) meeting in Chicago in a poster presentation. The abstract may be viewed on the Company web site...

Read more

BioInvent Announces Additional Efficacy Data from Intravenous Part of Phase 1/2 Trial with BI-1206 in Solid Tumors

June 7, 2023 7:15 AM

One additional patient has developed a partial response (PR) and one patient has remained on stable disease for over 80 weeksThese long-lasting responses in hard-to-treat metastatic diseases, in patients who had previously progressed after treatment with anti-PD1/PDL1 agents, strongly suggest that BI-1206 is enhancing and recovering the activity of pembrolizumab (an anti-PD1 agent)LUND, SWEDEN / ACCESSWIRE / June 7, 2023 / BioInvent...

Read more

AbTherx Announces License Agreement with Gilead

June 7, 2023 6:00 AM

License from Gilead grants AbTherx worldwide rights to a novel human therapeutic antibody discovery platformMOUNTAIN VIEW and SAN DIEGO, CA / ACCESSWIRE / June 7, 2023 / AbTherx, Inc., a privately held biotech company focused on accelerating the discovery and development of antibody therapeutics, today announced a license agreement with Gilead Sciences, Inc. (NASDAQ:GILD). The license agreement will provide AbTherx rights to Gilead's recently...

Read more

AbTherx Launches a Next-Generation Antibody Discovery Platform

June 7, 2023 6:00 AM

The company brings together a proven team and novel technologies to increase efficiencies in antibody discoveryMOUNTAIN VIEW and SAN DIEGO, CA / ACCESSWIRE / June 7, 2023 / AbTherx, Inc., a privately held biotech company with novel technologies that accelerate antibody discovery, announced the launch of its next-generation human antibody discovery platform. AbTherx's novel transgenic mouse technologies, Atlas™ Mice, include a clinically...

Read more

GeneTex Launches PD-L1 Antibody Comprehensively Validated by MS Validated Antibodies GmbH for Immunohistochemistry

June 6, 2023 9:00 AM

IRVINE, CA / ACCESSWIRE / June 6, 2023 / GeneTex, a multinational antibody manufacturing company, is leveraging its recombinant monoclonal antibody production platform to produce best-in-class biomedical research reagents. The specificity of these new antibodies is established through meticulous in-house validation testing based on knockdown/knockout methodologies complemented by other strategies. GeneTex has employed this process to develop and...

Read more

Ensysce Biosciences to Participate in Upcoming Industry Events

June 6, 2023 8:05 AM

Chief Medical Officer, Dr. William Schmidt, to Present at the CPDD 85th Annual Scientific MeetingChief Commercial Officer, Geoff Birkett, to Present Opening Address at EPHMRA 2023 Annual ConferenceSAN DIEGO, CA / ACCESSWIRE / June 6, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced two upcoming presentations in June. Chief Medical...

Read more

Applied Energetics Awarded $1.148 Million Phase II Small Business Technology Transfer Contract by the U.S. Army for Ultra-Broadband IRCM Source Development

June 5, 2023 4:00 PM

New contract funds ongoing development and testing of the Company's Infrared Countermeasure capabilities to disrupt electro-optic sensors.Phase II contract will be performed in collaboration with our university partner over a period of 24 months.TUCSON, AZ / ACCESSWIRE / June 5, 2023 / Applied Energetics, Inc. (OTCQB:AERG), a leader in the advancement of ultrashort pulse laser technologies (USPL), announced today that it has been awarded a...

Read more

Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)

June 5, 2023 8:05 AM

IFx-Hu2.0 demonstrated to have a promising safety profile at all 3 dose schedules tested5 of 7 (71%) of patients achieved durable systemic anti-tumor responses following IFx-Hu2.0 therapy and rechallenge with an immune checkpoint inhibitor (ICI) in patients who exhibited primary resistance to ICIsTranslational biomarker data underscores IFx-Hu2.0 mechanism; Demonstrates activation of systemic tumor-specific immune responsesData presented at the...

Read more

BioInvent to Present at Jefferies Healthcare Conference on June 8

June 5, 2023 4:20 AM

LUND, SE / ACCESSWIRE / June 5, 2023 / BioInvent International (STO:BINV) ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it will present the company at the Jefferies Healthcare Conference, taking place June 7-9 in New York. BioInvent management are also available for meetings during the...

Read more

UCM Technologies Inc. Presented a Revolutionary Three-Biomarker Signature Test for Early Stage (Stages I-II) Detection of Non-Small Cell Lung Cancer at the American Society of Clinical Oncology (ASCO) 2023 Meeting in Chicago IL

June 4, 2023 12:00 AM

CHICAGO, IL / ACCESSWIRE / June 4, 2023 / UCM Technologies has utilized a breakthrough combination of biomarkers (CA-62, CEA and CYFRA 21-1) to detect lung cancer at its earliest stages (stages I-II) with 93% sensitivity and 100% specificity.The CA-62 cancer biomarker is a mesenchymal N-glycoprotein with a branched chain of polysaccharides, and is expressed on the surface of epithelial-mesenchymal plasticity (EMP) transformed stem cells at their...

Read more

Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference

June 2, 2023 4:30 PM

BOSTON, MA / ACCESSWIRE / June 2, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory and cancer diseases, today announced that Stephen Yoder, president and chief executive officer of Pieris, will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 10:00 a.m....

Read more